Change in estimated GFR associates with coronary heart disease and mortality

Kunihiro Matsushita, Elizabeth Selvin, Lori D. Bash, Nora Franceschini, Brad C. Astor, Josef Coresh

Research output: Contribution to journalArticle

Abstract

Kidney function predicts cardiovascular and all-cause mortality, but little is known about the association of changes in estimated GFR (eGFR) with clinical outcomes. We investigated whether 3- and 9-yr changes in eGFR associated with risk for coronary heart disease (CHD) and all-cause mortality among 13,029 participants of the Atherosclerosis Risk in Communities (ARIC) Study. After adjustment for baseline covariates including eGFR in Cox proportional hazards models, the quartile of participants with the greatest annual decline (annual decline ≥5.65%) in eGFR were at significantly greater risk for CHD and all-cause mortality (hazard ratio 1.30 [95% confidence interval 1.11 to 1.52] and 1.22 [95% confidence interval 1.06 to 1.41], respectively) compared with the third quartile (annual decline between 0.33 and 0.47%). We observed similar results when we analyzed 9-yr changes in eGFR. Adjustment for covariates at the second eGFR used to estimate change reduced the association with CHD but not with mortality. Among participants with stage 3 chronic kidney disease, an increase in eGFR during the first 3 yr also associated with a higher risk for mortality, perhaps as a result of clinical instability. In conclusion, a steeper than average decline in eGFR associates with a higher risk for CHD and all-cause mortality. Increases in eGFR among participants with chronic kidney disease associate with similar increased risks.

Original languageEnglish (US)
Pages (from-to)2617-2624
Number of pages8
JournalJournal of the American Society of Nephrology
Volume20
Issue number12
DOIs
StatePublished - Dec 1 2009

Fingerprint

Coronary Disease
Mortality
Chronic Renal Insufficiency
Confidence Intervals
Proportional Hazards Models
Atherosclerosis
Kidney

ASJC Scopus subject areas

  • Nephrology

Cite this

Change in estimated GFR associates with coronary heart disease and mortality. / Matsushita, Kunihiro; Selvin, Elizabeth; Bash, Lori D.; Franceschini, Nora; Astor, Brad C.; Coresh, Josef.

In: Journal of the American Society of Nephrology, Vol. 20, No. 12, 01.12.2009, p. 2617-2624.

Research output: Contribution to journalArticle

@article{e23ae687ed184dc4abef60abe6f8aa18,
title = "Change in estimated GFR associates with coronary heart disease and mortality",
abstract = "Kidney function predicts cardiovascular and all-cause mortality, but little is known about the association of changes in estimated GFR (eGFR) with clinical outcomes. We investigated whether 3- and 9-yr changes in eGFR associated with risk for coronary heart disease (CHD) and all-cause mortality among 13,029 participants of the Atherosclerosis Risk in Communities (ARIC) Study. After adjustment for baseline covariates including eGFR in Cox proportional hazards models, the quartile of participants with the greatest annual decline (annual decline ≥5.65{\%}) in eGFR were at significantly greater risk for CHD and all-cause mortality (hazard ratio 1.30 [95{\%} confidence interval 1.11 to 1.52] and 1.22 [95{\%} confidence interval 1.06 to 1.41], respectively) compared with the third quartile (annual decline between 0.33 and 0.47{\%}). We observed similar results when we analyzed 9-yr changes in eGFR. Adjustment for covariates at the second eGFR used to estimate change reduced the association with CHD but not with mortality. Among participants with stage 3 chronic kidney disease, an increase in eGFR during the first 3 yr also associated with a higher risk for mortality, perhaps as a result of clinical instability. In conclusion, a steeper than average decline in eGFR associates with a higher risk for CHD and all-cause mortality. Increases in eGFR among participants with chronic kidney disease associate with similar increased risks.",
author = "Kunihiro Matsushita and Elizabeth Selvin and Bash, {Lori D.} and Nora Franceschini and Astor, {Brad C.} and Josef Coresh",
year = "2009",
month = "12",
day = "1",
doi = "10.1681/ASN.2009010025",
language = "English (US)",
volume = "20",
pages = "2617--2624",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "12",

}

TY - JOUR

T1 - Change in estimated GFR associates with coronary heart disease and mortality

AU - Matsushita, Kunihiro

AU - Selvin, Elizabeth

AU - Bash, Lori D.

AU - Franceschini, Nora

AU - Astor, Brad C.

AU - Coresh, Josef

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Kidney function predicts cardiovascular and all-cause mortality, but little is known about the association of changes in estimated GFR (eGFR) with clinical outcomes. We investigated whether 3- and 9-yr changes in eGFR associated with risk for coronary heart disease (CHD) and all-cause mortality among 13,029 participants of the Atherosclerosis Risk in Communities (ARIC) Study. After adjustment for baseline covariates including eGFR in Cox proportional hazards models, the quartile of participants with the greatest annual decline (annual decline ≥5.65%) in eGFR were at significantly greater risk for CHD and all-cause mortality (hazard ratio 1.30 [95% confidence interval 1.11 to 1.52] and 1.22 [95% confidence interval 1.06 to 1.41], respectively) compared with the third quartile (annual decline between 0.33 and 0.47%). We observed similar results when we analyzed 9-yr changes in eGFR. Adjustment for covariates at the second eGFR used to estimate change reduced the association with CHD but not with mortality. Among participants with stage 3 chronic kidney disease, an increase in eGFR during the first 3 yr also associated with a higher risk for mortality, perhaps as a result of clinical instability. In conclusion, a steeper than average decline in eGFR associates with a higher risk for CHD and all-cause mortality. Increases in eGFR among participants with chronic kidney disease associate with similar increased risks.

AB - Kidney function predicts cardiovascular and all-cause mortality, but little is known about the association of changes in estimated GFR (eGFR) with clinical outcomes. We investigated whether 3- and 9-yr changes in eGFR associated with risk for coronary heart disease (CHD) and all-cause mortality among 13,029 participants of the Atherosclerosis Risk in Communities (ARIC) Study. After adjustment for baseline covariates including eGFR in Cox proportional hazards models, the quartile of participants with the greatest annual decline (annual decline ≥5.65%) in eGFR were at significantly greater risk for CHD and all-cause mortality (hazard ratio 1.30 [95% confidence interval 1.11 to 1.52] and 1.22 [95% confidence interval 1.06 to 1.41], respectively) compared with the third quartile (annual decline between 0.33 and 0.47%). We observed similar results when we analyzed 9-yr changes in eGFR. Adjustment for covariates at the second eGFR used to estimate change reduced the association with CHD but not with mortality. Among participants with stage 3 chronic kidney disease, an increase in eGFR during the first 3 yr also associated with a higher risk for mortality, perhaps as a result of clinical instability. In conclusion, a steeper than average decline in eGFR associates with a higher risk for CHD and all-cause mortality. Increases in eGFR among participants with chronic kidney disease associate with similar increased risks.

UR - http://www.scopus.com/inward/record.url?scp=72049128645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72049128645&partnerID=8YFLogxK

U2 - 10.1681/ASN.2009010025

DO - 10.1681/ASN.2009010025

M3 - Article

C2 - 19892932

AN - SCOPUS:72049128645

VL - 20

SP - 2617

EP - 2624

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 12

ER -